key: cord-0912212-yur75j94
authors: Favresse, Julien; Bayart, Jean-Louis; Mullier, François; Dogné, Jean-Michel; Closset, Mélanie; Douxfils, Jonathan
title: Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
date: 2021-05-08
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.05.004
sha: 151f23eb6b4e4eb9fa647ec5d2a207e03f71cf53
doc_id: 912212
cord_uid: yur75j94

OBJECTIVES: Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimal dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims at investigate the early antibody response in a population of healthcare professionals having received two doses of the BNT162b2 mRNA COVID-19 vaccine. METHODS: The CRO-VAX HCP study is a multicenter, prospective, interventional study conducted in several sites in Belgium. The study included 231 healthcare professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by SARS-CoV-2 and 158 were uninfected and seronegative. In the first group, blood samples were collected at baseline and after 2, 4, 7, 10, 14, 21, and 28 days. In the second group, samples were obtained at baseline and after 14 and 28 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. RESULTS: In uninfected individuals, 95.5% (95% CI 91.0-98.2%) developed anti-spike antibodies after 14 days and a 24.9-fold rise (95% CI 21.4-28.9%) in antibody titer was observed after the second dose. In previously infected individuals, peak antibody response was reached after 7 days (i.e. 6,347 U/mL) and the second dose did not lead to significantly higher antibody titers (i.e. 8,856 to 11,911 U/mL). Antibody titers were higher in previously infected individuals. CONCLUSIONS: This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals.

The efficacy and safety of the two-dose regimen BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech, Mainz, Germany) has been proved and led in late December to its approval by several regulatory authorities [1] [2] [3] . Nevertheless, data on the immune response after two doses of BNT162b2 are so far limited [4] [5] [6] [7] . Additionally, individuals who had previous clinical or microbiological diagnosis of COVID-19 were excluded from pivotal clinical trials [2, 3, 6] , precluding the evaluation of the vaccine response in this particular subpopulation.

The CRO-VAX HCP study is a multicenter, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals having received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two-hundred and thirty-one volunteers from 3 medical centers in Belgium were enrolled. All participants provided informed consent prior to collection of data and specimen. The study was approved by the ethical committees of the 3 medical centers (approval number: 2020-006149-21). Participants received the first vaccine dose from January 18, 2021, to February 17, 2021. The second dose was administered 21 days after the first one. All volunteers underwent a blood drawn within 2 days before the first vaccine dose. Volunteers were then included in two follow-up protocols in a 1:2 ratio. In the first group, samples were collected at baseline and after 2, 4, 7, 10, 14, 21, and 28 days while in the second group, samples were obtained at baseline and after 14 and 28 days.

Antibodies against the SARS-CoV-2 nucleocapsid (anti-NCP; Elecsys Anti-SARS-CoV-2 NCP qualitative ECLIA, Roche Diagnostics, Machelen, Belgium) and the receptor binding domain of the S1 subunit of the spike protein (anti-S; Elecsys anti-SARS-CoV-2 spike quantitative ECLIA, Roche Diagnostics) were measured at each time point in all serum samples.

Statistical analysis was performed with GraphPad Prism 9.0.1 (GraphPad Software). Antibody titers between groups were tested using a Dunn's multiple comparisons test, with P < 0.05 considered significant.

In our cohort, 73.6% (n = 170) were females (mean age = 42.6 years; range, 23-66 years) and 26.4% 

In this study, we report a stronger humoral response in individuals with previous SARS-CoV-2 infection after the first dose of BNT162b2, supporting the concept that this first dose would act as a boost of a previous immunization, as also observed by others [4] [5] [6] [7] . This is further supported by the non-significant increase in antibody titers reported after the second dose compared to antibody titers already observed 7 days after the first dose. Evaluation of the pre-vaccinal serological status J o u r n a l P r e -p r o o f could therefore be proposed as a strategy to identify patients who will only require the booster dose [4] . Pan-immunoglobulin assays should be preferred in this context to ensure maximal sensitivity to previous SARS-CoV-2 immunization [8] . Further studies are however needed to determine whether a booster dose in previously infected patients or if a delayed administration of the second dose in uninfected persons could provide sufficient and effective long-term protection.

Our study has some limitations. The findings should be completed by the assessment of the neutralizing capacity of the anti-S antibodies and by investigation of the cellular immune response.

Importantly, while the conclusions of this study are of interest to support the concept of a single booster dose strategy in previously infected individuals, the efficacy of this dose regimen should be confirmed in a sufficiently powered study evaluating clinical outcomes.

This study (EudraCT registration number: 2020-006149-21) has a planned follow-up of two years. We would therefore be able to determine the long-term kinetics of the humoral response in both uninfected and previously infected participants.

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for up to 10 Months after Infection

Clinical Performance of the Elecsys Electrochemiluminescent Immunoassay for the Detection of SARS-CoV-2 Total Antibodies